We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sonus Pharmaceuticals (MM) | NASDAQ:SNUS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.2799 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 16, 2008
SONUS PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in its Charter)
Delaware |
|
000-21243 |
|
95-4343413 |
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
of incorporation) |
|
File Number) |
|
Identification No) |
1522 217 th Place S.E., Bothell, Washington 98021
(Address of principal executive offices)
(425) 487-9500
(Registrants telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
Sonus Pharmaceuticals, Inc., a Delaware corporation (the Company ), issued a press release on July 17, 2008, announcing that the Company received a notice from the NASDAQ Listing Qualifications Panel (the NASDAQ Panel ) on July 16, 2008 indicating that the NASDAQ Panel has determined to grant the Companys request to continue the listing of its securities on The NASDAQ Global Market. The press release is attached as Exhibit 99.1 hereto.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
|
Description |
|
|
|
Exhibit 99.1 |
|
Press release issued by Sonus Pharmaceuticals, Inc. on July 17, 2008. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
SONUS PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
Date: July 18, 2008 |
By: |
/s/ Alan Fuhrman |
|
|
Alan Fuhrman |
|
|
Senior Vice President and Chief Financial Officer |
3
Exhibit Index
Exhibit Number |
|
Description |
|
|
|
99.1 |
|
Press release issued by Sonus Pharmaceuticals, Inc. on July 17, 2008. |
4
1 Year Sonus Chart |
1 Month Sonus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions